EGFR and lung adenocarcinoma: Takehito et al 2010 had revealed that the EGFR-TKI, gefitinib was less effective in non-adenocarcinoma NSCLC with EGFR mutation than lung adenocarcinoma (LADC) harboring EGFR mutation.[45] Our study found that EGFR mutated LSCC patients had prior response to EGFR-TKIs than EGFR wild type LSCC patients, with higher object response rate (31.6% vs. 11.7%), disease control rate (72.0% vs. 42.8%) and longer progression-free survival (3.08 vs. 1.85 months).